Summary: In adults with obesity without diabetes, once-daily oral orforglipron 36 mg reduced body weight more than placebo at 72 weeks (-11.2%, 95% CI -12.0 to -10.4 vs -2.1%, 95% CI -2.8 to -1.4; P<0.001). Weight-loss response was dose related, but adverse-event discontinuation reached 10.3% in the orforglipron groups.
PICO Summary
| Element | Detail |
|---|---|
| Population | 3127 adults with obesity without diabetes; multinational phase 3, double-blind randomized trial with 72-week follow-up. |
| Intervention | Once-daily oral orforglipron 6 mg, 12 mg, or 36 mg plus diet and physical activity, assigned in a 3:3:3 ratio. |
| Comparison | Placebo plus the same lifestyle program, assigned in the fourth part of the 3:3:3:4 randomization scheme. |
| Outcome | Mean body-weight change at week 72 was -7.5% (95% CI -8.2 to -6.8), -8.4% (-9.1 to -7.7), and -11.2% (-12.0 to -10.4) with 6, 12, and 36 mg versus -2.1% (-2.8 to -1.4) with placebo (P<0.001 for all); with 36 mg, 54.6% vs 12.9% reached at least 10% weight loss, and adverse-event discontinuation was up to 10.3% vs 2.7%. |
Orforglipron for Obesity (ATTAIN-1)
Phase 3 RCT - obesity without diabetes - 72 weeks
Oral orforglipron reduced body weight more than placebo in adults with obesity without diabetes, with higher adverse-event discontinuation.
Expert Commentary
ATTAIN-1 shows that oral GLP-1 therapy can deliver clinically meaningful weight loss in obesity, but the effect size is still below the largest reductions reported with injectable incretin combinations. The 36 mg trial dose clearly beat placebo for weight loss and cardiometabolic markers, and the large, double-blind phase 3 design makes the efficacy signal credible. Can I use this with my patients? In the United States, yes for eligible adults: the FDA approved orforglipron as Foundayo on April 1, 2026, for chronic weight management in adults with obesity or overweight plus a weight-related comorbidity, alongside diet and physical activity. That said, the published ATTAIN-1 population excluded diabetes, so clinicians should match use to the approved indication and current label rather than extrapolate loosely. The practical questions are tolerability, adherence, access, and comparative value. Discontinuation for adverse events rose with dose, mostly from gastrointestinal effects, so this is not a no-trade-off oral alternative. Lilly funded the trial, which is expected in registration studies but still makes post-marketing effectiveness and safety data important. For patients who want an oral option and meet current criteria, this is now usable evidence, but not a reason to ignore monitoring, counselling, or cost.
References
Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774. PMID: 40960239.